Perlmutter Cancer Center Rankings & Awards | NYU Langone Health
NYU Langone’s Perlmutter Cancer Center is nationally recognized for cancer research and care.
Perlmutter Cancer Center—Rego Park | NYU Langone Health
Perlmutter Cancer Center—Rego Park offers infusion services, MRI, CT, nuclear medicine, bone density testing, mammography, and more.
Perlmutter Cancer Center Search Results | NYU Langone Health
We use cookies and similar tools to give you the best website experience. By using our site, you accept ...
Perlmutter Cancer Center Social Work Services | NYU Langone Health
The Department of Social Work Services at NYU Langone’s Perlmutter Cancer Center offers various support services for patients and caregivers during treatment.
Perlmutter Cancer Center—Sunset Park | NYU Langone Health
NYU Langone’s Perlmutter Cancer Center—Sunset Park offers radiation therapy and infusion treatment for all types of cancer and blood disorders.
Perlmutter Center for Women’s Imaging | NYU Langone Health
NYU Langone’s Perlmutter Center for Women’s Imaging offers mammography, breast ultrasound, and bone density testing.
Person-Centered Quality Measurement and Management in a System for Addictions Treatment in New York State (Project 1)
Person-Centered Quality Measurement and Management in a System for Addictions Treatment in New York State (Project 1)
Person-Centered Quality Measurement and Management in a System for Addictions Treatment in New York State (Project 2)
To drive change, OASAS will invest in a quality measurement and management (QM2) strategy that provides performance feedback to activate leadership and staff of clinics to improve practice as well as publicizes quality measures to ensure public accountability. Using the Donabedian framework as a guide, the OASAS QM2 strategy will include a suite of structural (e.g., client/counselor ratios), process (e.g., use of medications for OUD), and outcome (e.g., hospitalization for detoxification) quality measures. In support of the strategy, OASAS will also provide funding to ensure all clinics have electronic health records (EHR) that have capacity to capture and report on quality measures. The OASAS strategy will address common barriers to QM2 efforts, including: inadequate technological capacity at clinics, dearth of validated quality measures for SUD treatment, limited data literacy in the workforce, insufficient expertise in change management among staff, and clinic leadership resistance due to concerns about fairness in accounting for the clinical complexity of their clients. In addition, OASAS recognizes that gathering data directly from patients is essential to assessing whether their goals and needs are addressed in a person-centered system of care. OASAS will work with academic partners to develop measures and provide support to clinics to address these barriers. This QM2 research center (QM2-RC) proposal comes from an academic-government partnership that has a longstanding history of collaborating on studies to improve treatment for SUD. The broad aim is to build then test a science-based QM2 strategy for person-centered treatment. The project will leverage OASAS’s investment in its new QM2 strategy and policy leadership. The academic partners will offer expertise in statistical methods for measurement validation, risk adjustment, and causal inference that will address some obstacles to QM2 as well as build the evidence base for the benefits of the strategy. The team will also assess how clinics and other stakeholders—e.g., patients, payers—incorporate the QM2 strategy into practice improvement, contract negotiations, and choosing clinics.
Person-Centered Quality Measurement and Management in a System for Addictions Treatment in New York State (Project 3)
To drive change, OASAS will invest in a quality measurement and management (QM2) strategy that provides performance feedback to activate leadership and staff of clinics to improve practice as well as publicizes quality measures to ensure public accountability. Using the Donabedian framework as a guide, the OASAS QM2 strategy will include a suite of structural (e.g., client/counselor ratios), process (e.g., use of medications for OUD), and outcome (e.g., hospitalization for detoxification) quality measures. In support of the strategy, OASAS will also provide funding to ensure all clinics have electronic health records (EHR) that have capacity to capture and report on quality measures. The OASAS strategy will address common barriers to QM2 efforts, including: inadequate technological capacity at clinics, dearth of validated quality measures for SUD treatment, limited data literacy in the workforce, insufficient expertise in change management among staff, and clinic leadership resistance due to concerns about fairness in accounting for the clinical complexity of their clients. In addition, OASAS recognizes that gathering data directly from patients is essential to assessing whether their goals and needs are addressed in a person-centered system of care. OASAS will work with academic partners to develop measures and provide support to clinics to address these barriers. This QM2 research center (QM2-RC) proposal comes from an academic-government partnership that has a longstanding history of collaborating on studies to improve treatment for SUD. The broad aim is to build then test a science-based QM2 strategy for person-centered treatment. The project will leverage OASAS’s investment in its new QM2 strategy and policy leadership. The academic partners will offer expertise in statistical methods for measurement validation, risk adjustment, and causal inference that will address some obstacles to QM2 as well as build the evidence base for the benefits of the strategy. The team will also assess how clinics and other stakeholders—e.g., patients, payers—incorporate the QM2 strategy into practice improvement, contract negotiations, and choosing clinics.
PERSPECTIVES OF PROVIDERS ON HIGH QUALITY CARE OF LGBTQIA+ PATIENTS WITH INFLAMMATORY BOWEL DISEASE
This is a qualitative interview study to better understand provider attitudes and perspectives for providing high quality care in sexual and gender minorities (SGM) patients with inflammatory bowel disease (IBD).